Tuberculosis vaccine - Archivel Farma
Alternative Names: RUTILatest Information Update: 21 Feb 2023
At a glance
- Originator Archivel Farma
- Developer Archivel Farma; London School of Hygiene & Tropical Medicine; RUTI Immunotherapeutics
- Class Antineoplastics; Cancer vaccines; COVID-19 vaccines; Tuberculosis vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II COVID 2019 infections; Tuberculosis
- Phase I Allergic rhinitis; Asthma; Bladder cancer
Most Recent Events
- 10 Feb 2023 Archivel Farma withdrew the phase-II/III MYCOVIND trial in COVID-2019 infections due to decrease of incidence and severity of COVID and availability of therapeutic alternatives (NCT05115019)
- 22 Dec 2022 Archivel Farma completes a phase II RUTIVAC-1 trial in Tuberculosis (Prevention) in Spain (SC) (NCT03191578)
- 21 Dec 2022 Tuberculosis vaccine is still in phase I trials for Allergic rhinitis and Asthma (SC, Liposomal) in Spain (Archivel Farma pipeline, December 2022)